Mounjaro, Zepbound shortage eases
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years ...
"God knows what volume they're actually selling. And who knows? You're just taking it," one expert told The Post.
While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.